Mary Tagliaferri
Chief Tech/Sci/R&D Officer chez NEKTAR THERAPEUTICS
Fortune : 472 498 $ au 31/03/2024
Profil
Mary A.
Tagliaferri was the founder of Bionovo, Inc. (founded in 2002) where she held the title of President, Secretary, Treasurer & Director from 2011 to 2012.
She is currently working as an Independent Director at Enzo Biochem, Inc. (since 2020), as a Director at Y-mAbs Therapeutics, Inc. (since 2024), and as the Chief Medical Officer & Senior Vice President at Nektar Therapeutics (since 2015).
In her former positions, she worked as a Director at Atossa Therapeutics, Inc., as an Independent Director at Rayzebio, Inc. (from 2021 to 2024), as the Secretary, Treasurer & Chief Regulatory Officer at Lighten Up Enterprises International, Inc., and as the Chief Medical Officer at Kanglaite USA, Inc. (from 2012 to 2014).
Dr. Tagliaferri obtained her undergraduate degree from Cornell University in 1988, her doctorate degree from The University of California, San Francisco in 2002, and her graduate degree from the American College of Traditional Chinese Medicine in 1995.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ENZO BIOCHEM, INC.
0,61% | 31/01/2024 | 312 383 ( 0,61% ) | 396 726 $ | 31/03/2024 |
| 12/03/2024 | 4 660 ( 0,01% ) | 75 772 $ | 31/03/2024 |
Postes actifs de Mary Tagliaferri
| Sociétés | Poste | Début |
|---|---|---|
| NEKTAR THERAPEUTICS | Chief Tech/Sci/R&D Officer | 17/04/2023 |
| ENZO BIOCHEM, INC. | Director/Board Member | 17/11/2020 |
| Y-MABS THERAPEUTICS, INC. | Director/Board Member | 29/02/2024 |
Anciens postes connus de Mary Tagliaferri
| Sociétés | Poste | Fin |
|---|---|---|
| RAYZEBIO, INC. | Director/Board Member | 26/02/2024 |
| Kanglaite USA, Inc. | Chief Tech/Sci/R&D Officer | 01/06/2014 |
| BIONOVO INC. | Founder | 01/06/2012 |
| Lighten Up Enterprises International, Inc. | Chief Tech/Sci/R&D Officer | 05/07/2005 |
| ATOSSA THERAPEUTICS, INC. | Director/Board Member | - |
Formation de Mary Tagliaferri
| Cornell University | Undergraduate Degree |
| The University of California, San Francisco | Doctorate Degree |
| American College of Traditional Chinese Medicine | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| ENZO BIOCHEM, INC. | Health Technology |
| NEKTAR THERAPEUTICS | Health Technology |
| ATOSSA THERAPEUTICS, INC. | Health Technology |
| RAYZEBIO, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
| Lighten Up Enterprises International, Inc. | Finance |
Bionovo, Inc.
 Bionovo, Inc. Pharmaceuticals: MajorHealth Technology Bionovo, Inc. is a clinical drug discovery and development company, which is focused on developing drugs for the treatment of unmet medical needs in women's health and cancer. The company was founded by Isaac Cohen and Mary Tagliaferri in February 2002 and is headquartered in Emeryville, CA. | Health Technology |
| Y-mAbs Therapeutics, Inc. | |
| Kanglaite USA, Inc. |
